Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance & Regulatory Information

Guidance & Regulatory Information

                        Acts, Rules and Regulations
          Combination Products Guidance Documents
          Intercenter Consultative/ Collaborative Review Process
          Postmarketing Safety Reporting for Combination Products
          Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devices Home
          Combination Products
          Guidance & Regulatory Information
          Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devicesGuidance & Regulatory Information Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devices
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA announced some approved products are expected to transition from drug status to device status as a result of the U.S. Court of Appeals for the District of Columbia Circuit decision in Genus Medical Technologies v. FDA.

FDA intends to regulate products that meet the definitions of both devices and drugs as devices, including products the agency may have previously classified differently except where the statute indicates Congress intended a different classification.

FDA intends to publish a Federal Register notice with a list of approved drugs we tentatively determine should transition to device status as a result of this court decision. Stakeholders will have an opportunity to comment on those individual product determinations before the agency makes its final decisions on the classifications.

Sponsors of new drug applications or abbreviated new drug applications should pay the FY 2022 user fees by the due date to avoid being placed on the arrears list and incurring other penalties. Sponsors may request refunds for those fees, and FDA anticipates refunding user fees for those products that transition from drug status to device status. See the announcement for more information.

The comment period concerning the transition process and timeline closed November 30, 2021, however stakeholders may submit comments at any time.

No action is needed on marketed products until FDA notifies product sponsors. The agency will update this page as more information becomes available. Contact drug_device_transition_inquiry@fda.hhs.gov with questions.

Please contact combination@fda.gov with questions about other product classification or assignment issues unrelated to this notice.

                                                                                  Content current as of:
      12/01/2021Guidance & Regulatory Information

          
                        Acts, Rules and Regulations
          Combination Products Guidance Documents
          Intercenter Consultative/ Collaborative Review Process
          Postmarketing Safety Reporting for Combination Products
          Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devices
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop